249 related articles for article (PubMed ID: 35772010)
1. Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C.
Andraka-Christou B; Saloner B; Gordon AJ; Totaram R; Randall-Kosich O; Golan M; Stein BD
Am J Drug Alcohol Abuse; 2022 Jul; 48(4):492-503. PubMed ID: 35772010
[No Abstract] [Full Text] [Related]
2. Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorder.
Andraka-Christou B; Clark MH; Atkins DN; Del Pozo B
Subst Abus; 2022; 43(1):425-432. PubMed ID: 34236297
[No Abstract] [Full Text] [Related]
3. Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019.
Andraka-Christou B; Golan O; Totaram R; Ohama M; Saloner B; Gordon AJ; Stein BD
Ann Med; 2023 Dec; 55(1):514-520. PubMed ID: 36724766
[TBL] [Abstract][Full Text] [Related]
4. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
[TBL] [Abstract][Full Text] [Related]
5. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
6. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
Huhn AS; Hobelmann JG; Strickland JC; Oyler GA; Bergeria CL; Umbricht A; Dunn KE
JAMA Netw Open; 2020 Feb; 3(2):e1920843. PubMed ID: 32031650
[TBL] [Abstract][Full Text] [Related]
7. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
[TBL] [Abstract][Full Text] [Related]
8. Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
Andraka-Christou B; Atkins D
Am J Drug Alcohol Abuse; 2020 Nov; 46(6):749-760. PubMed ID: 32969757
[TBL] [Abstract][Full Text] [Related]
9. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
[No Abstract] [Full Text] [Related]
10. Estimating the impact on initiating medications for opioid use disorder of state policies expanding Medicaid and prohibiting substance use during pregnancy.
Choi S; Stein MD; Raifman J; Rosenbloom D; Clark JA
Drug Alcohol Depend; 2021 Dec; 229(Pt A):109162. PubMed ID: 34768053
[TBL] [Abstract][Full Text] [Related]
11. A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.
Taylor EN; Timko C; Binswanger IA; Harris AHS; Stimmel M; Smelson D; Finlay AK
Subst Abus; 2022; 43(1):556-563. PubMed ID: 34586978
[No Abstract] [Full Text] [Related]
12. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
[TBL] [Abstract][Full Text] [Related]
13. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
Pilarinos A; Bromberg DJ; Karamouzian M
JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707
[TBL] [Abstract][Full Text] [Related]
14. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
[TBL] [Abstract][Full Text] [Related]
15. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
[TBL] [Abstract][Full Text] [Related]
16. Attitudes toward and training in medications for opioid use disorders: a descriptive analysis among employees in the youth legal system and community mental health centers.
O'Reilly LM; Schwartz K; Brown SA; Dir A; Gillenwater L; Adams Z; Zapolski T; Hulvershorn LA; Aalsma M
Subst Abuse Treat Prev Policy; 2024 Jun; 19(1):32. PubMed ID: 38907286
[TBL] [Abstract][Full Text] [Related]
17. Spatial and Nonspatial Factors Associated with Access to Medication for Opioid Use Disorder among Pregnant Women in Massachusetts.
Joshi C; Ho Chui KK; Skeer MR; Stopka TJ
Subst Use Misuse; 2022; 57(13):1904-1917. PubMed ID: 36219099
[TBL] [Abstract][Full Text] [Related]
18. Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review.
Madden EF; Prevedel S; Light T; Sulzer SH
Subst Use Misuse; 2021; 56(14):2181-2201. PubMed ID: 34538213
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 and treating incarcerated populations for opioid use disorder.
Donelan CJ; Hayes E; Potee RA; Schwartz L; Evans EA
J Subst Abuse Treat; 2021 May; 124():108216. PubMed ID: 33288348
[TBL] [Abstract][Full Text] [Related]
20. Acceptance of medications for opioid use disorder in recovery housing programs in Missouri.
Wood CA; Duello A; Miles J; Lohmann B; Gochez-Kerr T; Richardson K; Anderson-Harper R; Winograd RP
J Subst Abuse Treat; 2022 Jul; 138():108747. PubMed ID: 35248406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
